Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC

Gilead Sciences, Inc. (GILD) entered into an exclusive option and license agreement with Tubulis, a Germany-based biotech company.The collaboration is aimed at discovering and developing an antibody-drug conjugate (ADC) against a solid tumor target.Gilead’s shares have risen 14.2% year to date against the industry's decline of 6.9%.Image Source: Zacks Investment ResearchMore on GILD’s Deal With TubulisThe single-asset focused collaboration, license and option agreement combines Tubulis’ differentiated ADC p ...